cas 51436-99-8|| where to buy 4-Bromo-2-fluorotoluene

Название продукции:4-Bromo-2-fluorotoluene

IUPAC Name:4-bromo-2-fluoro-1-methylbenzene

Упаковочная единица	Доступно для заказа	Цена ($)	Количество
CM253316-1000g	in stock	ŌǪŤ

Только для использования в НИОКР..

Форма запроса

Химическое название

Номер CAS

Количество*

Необходимые спецификации*
(% пробы, категория материала и т.д.)

Контактное лицо*

Электронная почта*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 51436-99-8 regularly via the above email.

Дополнительные примечания

Verification code*

refresh

: Номер CAS:51436-99-8; Молекулярная формула:C7H6BrF; Точка плавления:-; Smiles-код:C1=C(C(=CC=C1Br)C)F; Плотность:

: Номер в каталоге:CM253316; Молекулярная масса:189.03; Точка кипения:183.2°C at 760 mmHg; Номер Mdl:MFCD00013551; Хранение:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Crinecerfont; The New England Journal of Medicine publishes the primary CAHtalyst™ Adult Phase 3 study results of Crinecerfont for the treatment of congenital adrenal hyperplasia (CAH). Classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a rare genetic disorder, affected by a lack of cortisol and/or aldosterone. Corticotropin-releasing factor type 1 receptor (CRF1) antagonism is shown to clinically decrease ACTH production and adrenal androgen levels.
Neurocrine's Crinecerfont is an investigational, selective CRF1 antagonist being developed to reduce and control excess adrenocorticotropic hormone (ACTH) and adrenal androgens. The phase 3 study meets primary and important key secondary endpoints, including a significant reduction in androstenedione levels and lowering glucocorticoid dosing.